adorable baby smiling with joy
Peds Calc

PedsCalc Pro

No ads, plus saved calculations and notes in the Pro app.

$19.99/year, about $1.67/month. Cancel anytime.

Back to Valacyclovir Overview

Valacyclovir Indications and Approved Uses

When clinicians choose it in pediatrics

Valacyclovir converts rapidly to acyclovir, offering improved bioavailability and simplified dosing for HSV and varicella-zoster therapy in older children.

Looking for the dose calculator or main medication overview? Return to the main Valacyclovir page.

Primary Indications

Use episodic high-dose therapy for cold sores, daily suppression for frequent HSV recurrences, and early treatment for high-risk varicella or zoster. Monitor renal function and hydration.

Recurrent HSV labialis (cold sores)

Primary Use
Adolescents 12 years and olderRandomized trialsFirst-lineLabelDermatologic

Best results occur when taken at the earliest tingling or burning.

How to use

  • Dosing at a glance: 2 g at onset and 2 g 12 hours later.
  • Dose at the first prodrome for best efficacy.
  • Discuss suppressive therapy if outbreaks are frequent.
  • Reinforce sun and lip protection to reduce triggers.

Monitoring & follow-up

Parameters:

  • Lesion healing
  • Hydration
  • Adherence to prodrome dosing

Chronic HSV suppression

Primary Use
Children and adolescentsClinical trialsFirst-lineGuidelineDermatologic

Counsel on condom use and disclosure even with suppression.

How to use

  • Dosing at a glance: Off-label under 18 years (the label does not establish genital herpes use in patients under 18). Adult label suppression is 500 mg to 1 g once daily.
  • Counsel on transmission risk despite suppression.

Monitoring & follow-up

Parameters:

  • Outbreak frequency
  • Renal function
  • Adherence to suppression

Monitor / follow-up

  • Reassess every 6-12 months to evaluate continued need.
  • Monitor renal function annually and adjust dosing if needed.

Varicella-zoster treatment

Primary Use
Children and adolescentsModerateGuidelineGuidelineDermatologic

Consider IV acyclovir for severe or immunocompromised cases.

How to use

  • Dosing at a glance: Chickenpox: 20 mg/kg per dose (max 1 g) three times daily for 5 days, ages 2 to under 18 (label). Zoster: adult dose 1 g three times daily for 7 days; not established under 18 years.
  • Use in high-risk children and adolescents when started within 24 hours of rash onset.
  • Ensure hydration and adjust dosing for renal impairment.

Monitoring & follow-up

Parameters:

  • Rash progression
  • Hydration status
  • Neurologic symptoms

Monitor / follow-up

  • Monitor for neurologic involvement in zoster.

Secondary Clinical Uses

HSV-associated erythema multiforme prophylaxis

Secondary Use
Children and adolescentsExpert opinionSecond-lineConsensusSkin

Coordinate dermatology follow-up for taper plans.

How to use

  • Dosing at a glance: 500 mg once or twice daily for 6 months, then reassess.
  • Track lesion flares with photos and diaries.
  • Reassess after 6 months for taper or alternate therapy.
  • Provide rescue plans for breakthrough episodes.

Monitoring & follow-up

Parameters:

  • Breakthrough flares
  • Adherence
  • Side effects

Evidence Sources

Post-exposure prophylaxis for high-risk varicella contacts

Secondary Use
Immunocompromised adolescentsSpecialist consensusAdjunctGuidelineImmune

Consult infectious disease for immunocompromised hosts.

How to use

  • Dosing at a glance: 20 mg/kg/dose three times daily (max 1,000 mg/dose; max 3,000 mg/day) for 7 days, starting 7–10 days after exposure (JPIDS 2024 review).
  • Use when VZIG is unavailable or delayed.
  • Document immunity status and plan vaccination when eligible.

Monitoring & follow-up

Parameters:

  • Rash development
  • Fever
  • Hydration status

Monitor / follow-up

  • Monitor for rash and escalate to IV acyclovir if infection develops.

Off-Label Uses

Note: Off-label uses may be clinically appropriate based on evidence and expert consensus, but are not FDA-approved for these indications. Always consider the evidence base and document clinical reasoning.

Cytomegalovirus prophylaxis in renal transplant recipients

Off-Label
AdolescentsClinical trialsOff-labelOff-labelImmune

Reserve for valganciclovir intolerance.

How to use

  • Dosing at a glance: 2 g four times daily in select protocols.
  • Use only under transplant infectious disease guidance.
  • Switch to valganciclovir when tolerated.

Monitoring & follow-up

Parameters:

  • CBC and renal function
  • GI tolerance
  • Signs of CMV breakthrough

Monitor / follow-up

  • Monitor CBC and renal function closely.

Clinical Decision Support

When to start therapy

  • HSV prodrome or frequent recurrences requiring suppression.
  • High-risk varicella or zoster when started early.
  • Specialist-directed prophylaxis in immunocompromised hosts.

Triage questions

  • Is renal function adequate for dosing?
  • Is the patient immunocompromised or pregnant?
  • Can the family recognize prodrome symptoms?

Consult triggers

  • Suspected antiviral resistance or breakthrough disease.
  • Need for IV therapy (encephalitis or disseminated zoster).
  • Pregnancy in adolescents with HSV.

When to Reassess

Timeframe: 6-12 months for suppression or sooner if symptoms persist

Key criteria to review:

  • Breakthrough outbreaks
  • Renal function decline
  • Adverse effects

Next steps: Adjust dosing, confirm adherence, or consider alternative antivirals.

Care & Monitoring Highlights

Monitoring priorities

  • Baseline renal function and hydration status.
  • Assess for neurologic symptoms in high-dose therapy.
  • Review outbreak logs annually for suppressive therapy.

Caregiver counseling

  • Valacyclovir lowers but does not eliminate HSV transmission.
  • Ensure adequate hydration during therapy.
  • Do not share medication with others.

By Age Group

children

  • Selected varicella treatment
  • HSV suppression under specialist guidance

adolescents

  • Cold sore episodic therapy
  • HSV suppression
  • Varicella prophylaxis when high risk

Alternative Medication Options

Acyclovir

Alternative

Younger children needing liquid formulations

Advantages
  • More pediatric data
Disadvantages
  • More frequent dosing

Famciclovir

Alternative

HSV suppression in teens with valacyclovir intolerance

Advantages
  • Alternative agent
Disadvantages
  • Tablet only

Valganciclovir

Alternative

CMV prophylaxis

Advantages
  • Preferred CMV agent
Disadvantages
  • Cytopenia risk

Parent Communication Guide

When This Medicine Helps

Understanding the Condition

Valacyclovir treats herpes viruses and helps shorten outbreaks.

Why We Choose This Medicine

It is easier to take than acyclovir and helps reduce outbreaks.

What to Expect

Most children improve within a few days if taken early.

Monitoring Your Child

Signs the Medicine is Working:

  • Shorter outbreaks
  • Less pain or itching
  • Fewer recurrences

When to Contact Your Doctor:

No improvement after: No improvement after the expected treatment window

Watch for these warning signs:

  • Confusion or agitation
  • Severe dehydration
  • New widespread rash

What to do: Seek urgent care and contact the care team for severe symptoms.

Common Parent Questions

Should we start at the first tingling?

Yes, early dosing works best.

Does it prevent transmission?

It lowers but does not eliminate risk.

What if we miss a dose?

Give it when you remember unless it is close to the next dose. Do not double up.

Key messages for families

  • Start early at the first sign of outbreak.
  • Hydrate well during therapy.
  • Call for confusion or severe dehydration.

Home care tips

  • Keep outbreak logs and triggers.
  • Track urine output during febrile illness.
  • Use sunscreen to reduce HSV triggers.

Never Use Valacyclovir For

Empiric treatment of nonspecific rashes without HSV or VZV suspicion.

Alternatives: Consult prescribing references for suitable substitutes.

Infants younger than label age without specialist guidance.

Alternatives: Consult prescribing references for suitable substitutes.

Patients with untreated severe dehydration or acute kidney injury.

Alternatives: Consult prescribing references for suitable substitutes.

Last updated: 2/27/2026•Evidence quality: 86/10
Back to Overview

References

  1. Valacyclovir LabelDailyMed, 2024https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7696a2e0-c7f9-47a0-a7d3-d14fd9301be8
  2. Sexually Transmitted Infections Treatment Guidelines - HerpesCenters for Disease Control and Prevention, 2024https://www.cdc.gov/std/treatment-guidelines/herpes.htm
  3. Valaciclovir for viral infectionsMedicines for Children, 2024https://www.medicinesforchildren.org.uk/medicines/valaciclovir-for-viral-infections/
  4. Varicella post-exposure prophylaxis review (Journal of the Pediatric Infectious Diseases Society)Journal of the Pediatric Infectious Diseases Society, 2024https://academic.oup.com/jpids/article/13/1/69/7439837
  5. Clinical Overview of VaricellaCenters for Disease Control and Prevention, 2024https://www.cdc.gov/chickenpox/hcp/clinical-overview.html
  6. Clinical Practice Guideline for the Management of Herpes ZosterInfectious Diseases Society of America, 2016https://www.idsociety.org/practice-guideline/herpes-zoster/
  7. Erythema MultiformeStatPearls, 2024https://www.ncbi.nlm.nih.gov/books/NBK482338/
  8. Valacyclovir for CMV Prophylaxis in Pediatric Renal TransplantPediatric Transplantation, 2022https://doi.org/10.1111/petr.14080